Ludimila Cavalcante

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Dustin A. Deming, Ludimila Cavalcante, Sam Joseph Lubner et al. · Investigational New Drugs · 2015 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells

Gary Shaw, Ludimila Cavalcante, Francis J. Giles et al. · Journal of Hematology & Oncology · 2022 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17

Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis

Ludimila Cavalcante · Clinical ophthalmology · 2010 · 39 citations · Full text

Medicine, Ophthalmology, Surgery +13

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

Ludimila Cavalcante, Jose Lutzky, Asim Amin · Cancer Management and Research · 2015 · 32 citations · Full text

Medicine, Nephrology, Oncology +14

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Andrew Hsu, Kelsey E. Huntington, André De Souza et al. · Cancer Biology & Therapy · 2022 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17